author-photo

Michael B. Atkins

Georgetown University
Harvard University

481

Papers

44857

Citations

Citation Trend

Filter By

Papers (317) Sort By

Journal Conference Others

TIVO-3: Age-related tolerability outcomes of tivozanib versus sorafenib in metastatic relapsed or refractory renal cell carcinoma, a subgroup analysis of the TIVO-3 clinical trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
TIVO-3: Durability of response and updated overall survival of tivozanib versus sorafenib in metastatic renal cell carcinoma (mRCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT188: IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC)

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Immunotherapy Utilization Among Patients With Metastatic NSCLC: Impact of Comorbidities.

2021 Journal of Immunotherapy
Show All
- Source
- Cite
- Save
Citations (0)
Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)